GlassScriptPhysician profile
Adam Scott Berger
NPI 1972574408
$16,520.44
in general payments reported to CMS, 2019-2025
24 companies · $6,237 in 2025
The $6,237 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $56.64 · 2021: $76.10 · 2022: $373 · 2023: $615 · 2024: $8,869 · 2025: $6,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,980 · Food and Beverage: $4,303 · Travel and Lodging: $3,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,980.00 |
| Food and Beverage | $4,302.76 |
| Travel and Lodging | $3,438.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $10,016.46 | 2024-2025 | |
| US Oncology Corporate, INC. | $1,861.10 | 2024-2025 | |
| Kyowa Kirin, INC. | $1,420.46 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $814.69 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $522.92 | 2022-2025 | Vabysmo, Lucentis |
| Astellas Pharma US INC | $483.01 | 2023-2025 | Izervay |
| Alcon Research LLC | $353.95 | 2025 | |
| Bausch & Lomb Americas INC. | $199.09 | 2022-2023 | Xipere |
| Novartis Pharmaceuticals Corporation | $185.63 | 2019-2021 | |
| Abbvie INC. | $182.62 | 2022-2025 | Ozurdex |
| Johnson & Johnson Surgical Vision, INC. | $107.23 | 2025 | |
| Allergan, INC. | $103.31 | 2019-2020 | |
| Sandoz INC. | $97.63 | 2024-2025 | Cimerli |
| Regeneron Pharmaceuticals, INC. | $52.70 | 2023 | Eylea |
| Dutch Ophthalmic, USA | $37.68 | 2024 | Eva, Combined Machine, Tissueblue |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $34.92 | 2023 | |
| Biogen, INC. | $23.73 | 2023 | |
| Apellis Pharmaceuticals, INC. | $23.31 | 2025 | Syfovre |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.